The recent availability of enzyme replacement therapy (ERT) with recombinant human GALNS (elosulfase alfa; Vimizin®; BioMarin Europe Ltd., London, UK) has provided systemic treatment for MPS IVA when added to traditional symptom-based management. This evidence concerns the gene GALNS and mucopolysaccharidosis type 4A.